SynthesisFrontiers in immunology2026
From mechanism to clinical: research evolution and hotspot analysis of CD276/B7-H3 in cancer immunotherapy.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CD276 (B7-H3) is a pivotal immune checkpoint molecule with dual roles in T-cell regulation and tumor immune evasion, representing a promising therapeutic target across multiple cancers. However, a comprehensive analysis of the research landscape, evolutionary pathways, and knowledge structure in this field remains lacking. Methods: Publications related to CD276/B7-H3 in cancer research were systematically retrieved from the Web of Science Core Collection (WoS, n = 688) and Scopus (n = 759) spanning from January 2001 to August 2025. After merging and de-duplication, a final corpus of 830 publications was analyzed using Bibliometrix, VOSviewer, CiteSpace, and Pajek to evaluate publication trends, influential authors and institutions, collaboration networks, core journals, co-citation patterns, and keyword evolution. Results: The field exhibited exponential growth with an annual publication increase of 21.77%. China and the United States were the dominant contributing countries. Journal for Immunotherapy of Cancer was the most productive journal, while Clinical Cancer Research produced the most impactful publications. Co-citation analysis highlighted foundational studies on B7-H3's prognostic significance and recent breakthroughs in CAR T-cell therapy targeting B7-H3. Keyword evolution revealed a clear transition from early themes such as "expression" and "prognosis" to contemporary focuses including "immunotherapy," "tumor microenvironment," and "chimeric antigen receptor". Conclusion: This study provides the first integrated bibliometric overview of CD276/B7-H3 research in cancer, illustrating a rapid transition from mechanistic exploration to clinical application. The findings underscore B7-H3's importance as a pan-cancer antigen and immunotherapeutic target, offering valuable insights for guiding future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.